Veeva Systems is a best-in-class life sciences software business with 28% net margins, 134% free cash flow conversion, and a four-quarter earnings beat streak, but a confirmed price downtrend with the 50-day moving average crossing below the 200-day moving average blocks near-term entry despite attractive analyst upside of 51%.
Thesis pillars
- Best In Class Margins Fcf→Stable
- Consistent Earnings Beat Record↓Deteriorating
- Death Cross Momentum Downtrend↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Veeva Systems Inc. (VEEV) Stock Analysis
Range Bound setup · Temporary headwind edge
Healthcare · Health Information Services
Wait for pullback to $185.01. At $186.24 the A.R:R is 1.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $185.01 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Geographic: North America; Negative momentum.
Veeva provides cloud software, data, and consulting to the global life sciences industry through four product suites—Commercial, Data, Development, and Quality Cloud—serving 1,552 customers including major pharma and biotech companies as of January 31, 2026. Revenue comes from... Read more
Wait for pullback to $185.01. At $186.24 the A.R:R is 1.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $185.01 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Geographic: North America; Negative momentum. Chart setup: RSI 44 mid-range, Bollinger mid-band. Wide-moat business. Accumulate on weakness. Score 6.1/10, moderate confidence.
Passes 5/9 gates (clean insider activity, news events none recent, earnings proximity 39d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
About Veeva Systems Inc.
About Veeva Systems Inc.
Veeva's cloud platform serves 1,552 life sciences customers as of January 31, 2026—spanning pharmaceutical, biotechnology, and medical device companies across the globe—with customers outside North America generating approximately 40% of total revenues. The company employed 7,928 people, up by 637 from the prior year, supporting four product suites: Commercial Cloud, Development Cloud, Quality Cloud, and Data Cloud.
Veeva generates revenue through subscriptions to cloud applications and professional services, organized into two reporting tracks—Commercial Solutions (Commercial Cloud and Data Cloud) and R&D and Quality Solutions (Development Cloud and Quality Cloud)—sold through a direct sales force aligned to pharmaceutical and biotechnology customers' separate commercial and R&D decision-making structures. The Commercial Cloud includes Vault CRM, the successor to Veeva CRM, which relies on the Salesforce platform and will be supported only through December 31, 2029. Data products—including Veeva OpenData, Compass, and Link—compete with IQVIA Holdings, Ipsos, and Definitive Health. The Development Cloud and Quality Cloud address clinical trial management, regulatory submissions, and quality management, competing with IQVIA, Dassault Systèmes, Oracle, and OpenText. Top-10 customers accounted for 28% of total revenues in each of the three fiscal years ended January 31, 2026, 2025, and 2024—stable concentration in a blue-chip customer base.
Show full overview
Veeva CRM relies on the Salesforce platform until December 31, 2029, and the migration to Vault CRM carries execution risk: Salesforce has announced that certain large Veeva CRM customers have committed to purchasing its CRM solutions, and Veeva acknowledges other customers may follow. If migration to Vault CRM encounters disruptions or delays, or if additional customers move to Salesforce, Commercial Cloud subscription revenue could be adversely affected across multiple renewal cycles. The 10-K also identifies cybersecurity threats as a material risk given the platform stores clinical trial data, regulatory submissions, and patient information.
See also: Healthcare · Health Information Services
From Veeva Systems Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-07-26Recent Developments — Veeva Systems Inc.
Latest news
- NEWS Bogart Wealth LLC Grows Stake in Veeva Systems Inc. $VEEV - MarketBeat — MarketBeat positive
- NEWS /C O R R E C T I O N -- Veeva Systems/ - PR Newswire — PR Newswire neutral
- NEWS Merck KGaA, Darmstadt, Germany Selects Veeva Vault CRM Worldwide - PR Newswire — PR Newswire positive
- NEWS Veeva Systems (VEEV) to Release Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS Veeva Systems (VEEV) is a top-ranked growth stock: Should you buy? - MSN — MSN positive
Generated 2026-07-26T08:02:05Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomertop 10 customers28%10-K Item 1A: 'our top 10 customers accounted for 28% of our total revenues'
- HIGHGeographicNorth America10-K Item 1A: 'customers outside North America accounted for approximately 40% of our total revenues'
Material Events(8-K, last 90d)
- 2026-04-20Item 5.02MEDIUMJosh Faddis, SVP and General Counsel, intends to retire effective November 1, 2026, transitioning to a part-time advisor role. Veeva will appoint a successor upon his transition. No reason cited beyond retirement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $185.01. At $186.24 the A.R:R is 1.3:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $185.01 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Geographic: North America; Negative momentum. Chart setup: RSI 44 mid-range, Bollinger mid-band. Wide-moat business. Accumulate on weakness. Target $219.73 (+18.0%), stop $170.22 (−9.4%), A.R:R 1.3:1. Score 6.1/10, moderate confidence.
Take-profit target: $219.73 (+18.0% upside). Target $219.73 (+18.0%), stop $170.22 (−9.4%), A.R:R 1.3:1. Stop-loss: $170.22.
Concentration risk — Geographic: North America; Negative momentum; Below 200-MA, MA slope -7.0%/30d (confirmed downtrend).
Veeva Systems Inc. trades at a P/E of 31.8 (forward 18.6). TrendMatrix value score: 5.6/10. Verdict: Buy (Wait for Entry).
35 analysts cover VEEV with a consensus score of 3.9/5. Average price target: $244.
What does Veeva Systems Inc. do?Veeva provides cloud software, data, and consulting to the global life sciences industry through four product...
Veeva provides cloud software, data, and consulting to the global life sciences industry through four product suites—Commercial, Data, Development, and Quality Cloud—serving 1,552 customers including major pharma and biotech companies as of January 31, 2026. Revenue comes from subscriptions and professional services, with 7,928 employees. The platform is deeply embedded in regulated workflows for clinical trials, regulatory submissions, CRM, and quality management.